AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10334230 — intervention group
Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 20
Study 10334230 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nasal decongestant (oxymetazoline hydrochloride, 0.2 mg per nostril)
Number of subjects: 20
Study 10334230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of decongestant and ENDS
Number of subjects: 20
Study 10334230 — intervention group
Group type: COMPARATOR
Intervention: Control (without ENDS)
Number of subjects: 20
Study 7503003 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine ER
Number of subjects: 180
Study 7503003 — intervention group
Group type: EXPERIMENTAL
Intervention: combined felodipine/simvastatin therapy
Number of subjects: 180
Study 7503003 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 2021284 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg/day of Diltiazem
Number of subjects: 18
Study 2021284 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day of Nifedipine
Number of subjects: 18
Study 2021284 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg/day of Diltiazem with 30 mg/day of Nifedipine
Number of subjects: 18
Study 2021284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2021284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Diltiazem and Nifedipine
Number of subjects: 18
Study 2021284 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem alone
Number of subjects: 18
Study 7051796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (200 mg daily)
Number of subjects: 32
Study 7051796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7051796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine
Number of subjects: 32
Study 7051796 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine and Placebo
Number of subjects: 32
Study 28976841 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair (n=35, 20 AM, 15 RC)
Number of subjects: 34
Study 28976841 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement (n=43, 21 AM, 22 RC)
Number of subjects: 34
Study 28976841 — intervention group
Group type: COMPARATOR
Intervention: Positive control (n=71, 49 AM, 22 RC)
Number of subjects: 34
Study 28976841 — intervention group
Group type: COMPARATOR
Intervention: Negative control (n=18, 10 AM, 8 RC)
Number of subjects: 34
Study 27855441 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening (Safety arm)
Number of subjects: 12278
Study 27855441 — intervention group
Group type: COMPARATOR
Intervention: Liquid Based Cytology (LBC) screening (Control arm)
Number of subjects: 12278
Study 27855441 — intervention group
Group type: EXPERIMENTAL
Intervention: LBC screening at 24 months (Safety arm)
Number of subjects: 12278
Study 27855441 — intervention group
Group type: COMPARATOR
Intervention: LBC screening at 24 months (Control arm)
Number of subjects: 12278
Study 24445291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (400, 10,000, or 40,000 IU/d)
Number of subjects: 63
Study 24445291 — intervention group
Group type: COMPARATOR
Intervention: Combined higher-dose groups (10,000 and 40,000 IU/d)
Number of subjects: 63
Study 23559286 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Intervals (HIT, n = 12)
Number of subjects: 43
Study 23559286 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance (R, n = 8)
Number of subjects: 43
Study 23559286 — intervention group
Group type: COMPARATOR
Intervention: Combined group (HIT + R, n = 10)
Number of subjects: 43
Study 23559286 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 13)
Number of subjects: 43
Study 20017599 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of azacitidine and cytarabine
Number of subjects: 34
Study 18997910 — intervention group
Group type: EXPERIMENTAL
Intervention: Power brush with wireless display
Number of subjects: 61
Study 18997910 — intervention group
Group type: COMPARATOR
Intervention: Power brush alone
Number of subjects: 61
Study 16436127 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) treatment
Number of subjects: 0
Study 16436127 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative HBV DNA levels
Number of subjects: 0
Study 16436127 — intervention group
Group type: EXPERIMENTAL
Intervention: Log HBV DNA testing at week 12
Number of subjects: 0
Study 16436127 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA at baseline and decrease in HBV DNA from baseline to week 12
Number of subjects: 0
Study 16436127 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg levels
Number of subjects: 0
Study 14552410 — intervention group
Group type: EXPERIMENTAL
Intervention: Earnings-supplement policies
Number of subjects: 2
Study 11933488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing (Aquacel)
Number of subjects: 100
Study 11933488 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing (Sorbsan)
Number of subjects: 100
Study 8690551 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-assisted angioplasty
Number of subjects: 0
Study 8690551 — intervention group
Group type: COMPARATOR
Intervention: Standard angioplasty
Number of subjects: 0
Study 1818389 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral artesunate (1200, 600, 650 mg total doses)
Number of subjects: 0
Study 1818389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether (480 mg)
Number of subjects: 0
Study 1818389 — intervention group
Group type: COMPARATOR
Intervention: Shorter courses of treatment
Number of subjects: 0
Study 1818389 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 0
Study 1818389 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematological effects
Number of subjects: 0
Study 6355321 — intervention group
Group type: EXPERIMENTAL
Intervention: HuIFN‐alpha 2, 8.4 X 10(6) U/day
Number of subjects: 52
Study 6355321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30040525 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate teaching group (parents taught smartphone otoscopy and cerumen removal at the first visit)
Number of subjects: 699
Study 30040525 — intervention group
Group type: COMPARATOR
Intervention: Delayed teaching group (parents received teaching intervention after 1 week's independent use)
Number of subjects: 699
Study 30040525 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate teaching group
Number of subjects: 699
Study 30040525 — intervention group
Group type: COMPARATOR
Intervention: Delayed teaching group
Number of subjects: 699
Study 30040525 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' experience with smartphone otoscopy
Number of subjects: 699
Study 27594054 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual modality (ASL with English closed captioning)
Number of subjects: 150
Study 27594054 — intervention group
Group type: COMPARATOR
Intervention: Monolingual modality (English text)
Number of subjects: 150
Study 25716702 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) 6 mg daily for 5 days, started within 24 hours of admission.
Number of subjects: 0
Study 25716702 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 0
Study 24680232 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 34
Study 24680232 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control (WLC)
Number of subjects: 34
Study 23067919 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900
Study 23067919 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study 19324916 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 (0.8 microg kg(‐1) bolus; 0.113 microg kg(‐1) h(‐1) infusion)
Number of subjects: 80
Study 19324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1000 mg bolus)
Number of subjects: 80
Study 19324916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both T3 and methylprednisolone
Number of subjects: 80
Study 19324916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17531887 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NaFeEDTA (56 mg/kg)
Number of subjects: 516
Study 17531887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NaFeEDTA (28 mg/kg)
Number of subjects: 516
Study 17531887 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolytic iron (56 mg/kg)
Number of subjects: 516
Study 17531887 — intervention group
Group type: COMPARATOR
Intervention: Unfortified whole maize flour (control group)
Number of subjects: 516
Study 15383086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed tissue Doppler imaging during dobutamine stress testing
Number of subjects: 26
Study 15383086 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine stress testing
Number of subjects: 26
Study 11468502 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing health information to residents of Boise, ID
Number of subjects: 5909
Study 11468502 — intervention group
Group type: COMPARATOR
Intervention: Control cities (not specified)
Number of subjects: 5909
Study 9710167 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkabout Orthosis (WO)
Number of subjects: 10
Study 9710167 — intervention group
Group type: COMPARATOR
Intervention: Isocentric Reciprocal Gait Orthosis (IRGO)
Number of subjects: 10
Study 7527406 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta-estradiol (E2) 10 mg E2 valerate
Number of subjects: 2
Study 2921874 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 12
Study 2921874 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (222 ng/kg per min)
Number of subjects: 12
Study 30395144 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom monitoring intervention
Number of subjects: 150
Study 28888275 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic optimization (MAP 85-100 mm Hg, SVO2 65%-75%)
Number of subjects: 112
Study 28888275 — intervention group
Group type: COMPARATOR
Intervention: Standard care strategy (MAP 65 mm Hg)
Number of subjects: 112
Study 28888275 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic optimization
Number of subjects: 112
Study 28888275 — intervention group
Group type: COMPARATOR
Intervention: Standard care strategy
Number of subjects: 112
Study 25459097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate-emtricitabine (TDF-FTC)
Number of subjects: 739
Study 25459097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 739
Study 23497119 — intervention group
Group type: EXPERIMENTAL
Intervention: Job-specific workers' health surveillance (WHS)
Number of subjects: 899
Study 22254717 — intervention group
Group type: EXPERIMENTAL
Intervention: WCDMA RF exposure for 30 minutes
Number of subjects: 20
Study 22254717 — intervention group
Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 20
Study 18849613 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-gamma (IFN-gamma)
Number of subjects: 0
Study 18849613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16618907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of surgery, radiation therapy, and chemotherapy (cisplatin and paclitaxel) along with intraoperative radiation therapy
Number of subjects: 32
Study 15131760 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-mg transdermal nicotine patch
Number of subjects: 34
Study 11900420 — intervention group
Group type: EXPERIMENTAL
Intervention: Panels with sensor lines and compatible linkages
Number of subjects: 96
Study 11900420 — intervention group
Group type: EXPERIMENTAL
Intervention: Panels with sensor lines and incompatible linkages
Number of subjects: 96
Study 11900420 — intervention group
Group type: COMPARATOR
Intervention: Compatible panels without sensor lines
Number of subjects: 96
Study 11900420 — intervention group
Group type: COMPARATOR
Intervention: Incompatible panels without sensor lines
Number of subjects: 96
Study 10087976 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 4-hour infusion of 1500 mg Clodronate
Number of subjects: 0
Study 10087976 — intervention group
Group type: COMPARATOR
Intervention: Traditional 2-hour infusion of 300 mg Clodronate
Number of subjects: 0
Study 8092591 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal sufentanil and midazolam (IN‐SM)
Number of subjects: 0
Study 8092591 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular meperidine, promethazine, and chlorpromazine (IM‐MPC)
Number of subjects: 0
Study 3134266 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms q.i.d.)
Number of subjects: 90
Study 3134266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg q.i.d.)
Number of subjects: 90
Study 3134266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 3134266 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 90
Study 3134266 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 90
Study 30239519 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cryotherapy (ice chips held in mouth during chemotherapy infusion)
Number of subjects: 80
Study 30239519 — intervention group
Group type: COMPARATOR
Intervention: Usual care (sodium bicarbonate mouthwash postchemotherapy)
Number of subjects: 80
Study 28096255 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation plus usual care
Number of subjects: 326
Study 28096255 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 326
Study 26496205 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TENS (50 Hz, 15 min/day for 5 days)
Number of subjects: 36
Study 26496205 — intervention group
Group type: COMPARATOR
Intervention: Sham TENS
Number of subjects: 36
Study 23645097 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Assessment Battery (TAB)
Number of subjects: 1548
Study 23645097 — intervention group
Group type: COMPARATOR
Intervention: Traditional in-person Cognitive Assessment Battery
Number of subjects: 1548
Study 23645097 — intervention group
Group type: COMPARATOR
Intervention: Telephone Interview for Cognitive Status (TICS)
Number of subjects: 1548
Study 21546387 — intervention group
Group type: EXPERIMENTAL
Intervention: eSET
Number of subjects: 177
Study 21546387 — intervention group
Group type: COMPARATOR
Intervention: DET
Number of subjects: 177
Study 18990201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299 (Lp299)
Number of subjects: 50
Study 18990201 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine (CHX)
Number of subjects: 50
Study 17144916 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 microg
Number of subjects: 32
Study 17144916 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg
Number of subjects: 32
Study 17144916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12571167 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 37
Study 12571167 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH
Number of subjects: 37
Study 12571167 — intervention group
Group type: EXPERIMENTAL
Intervention: rFSH and rLH (225 IU/day)
Number of subjects: 37
Study 12571167 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH (225 IU/day)
Number of subjects: 37
Study 12571167 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH (450 IU/day)
Number of subjects: 37
Study 12571167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12088604 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidebook for self-care and doctor/patient interaction
Number of subjects: 136
Study 9686822 — intervention group
Group type: EXPERIMENTAL
Intervention: rhG‐CSF (10 microg/kg) administered for 3 consecutive days (0, 1, 2)
Number of subjects: 62
Study 9686822 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhG‐CSF)
Number of subjects: 62
Study 7900230 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection
Number of subjects: 32
Study 7900230 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 32
Study 7900230 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection (for tumors > 2.0 cm)
Number of subjects: 32
Study 7900230 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy (for tumors > 2.0 cm)
Number of subjects: 32
Study 7900230 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited resection (for adenocarcinoma)
Number of subjects: 32
Study 7900230 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy (for adenocarcinoma)
Number of subjects: 32
Study 2680679 — intervention group
Group type: EXPERIMENTAL
Intervention: W14859 (liquid thrombin)
Number of subjects: 29
Study 974460 — intervention group
Group type: EXPERIMENTAL
Intervention: Ge(Li) detector scanner
Number of subjects: 165
Study 974460 — intervention group
Group type: COMPARATOR
Intervention: NaI (Tl) detectors
Number of subjects: 165
Study 30711917 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Operating Procedure (SOP) for PCV measurement
Number of subjects: 57
Study 30711917 — intervention group
Group type: COMPARATOR
Intervention: No Standard Operating Procedure (No SOP) for PCV measurement
Number of subjects: 57
Study 28235210 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 130
Study 25048750 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) 60 mg/d
Number of subjects: 2503
Study 25048750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2503
Study 24868256 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic oral capsules
Number of subjects: 173
Study 24868256 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal capsules with probiotics
Number of subjects: 173
Study 24868256 — intervention group
Group type: COMPARATOR
Intervention: Classical antibiotic therapy
Number of subjects: 173
Study 21109462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.1 μg/kg/min (Group 1)
Number of subjects: 60
Study 21109462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.2 μg/kg/min (Group 2)
Number of subjects: 60
Study 21109462 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study 19086773 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 32
Study 19086773 — intervention group
Group type: COMPARATOR
Intervention: 0 mg nicotine gum
Number of subjects: 32
Study 19086773 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette abstinence
Number of subjects: 32
Study 17156425 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 8
Study 17156425 — intervention group
Group type: EXPERIMENTAL
Intervention: Prometheus
Number of subjects: 8
Study 12627468 — intervention group
Group type: EXPERIMENTAL
Intervention: naloxone (125 microg/kg)
Number of subjects: 30
Study 12627468 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 10677394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of high dose (250 mg/250 mg) of lactulose/rhamnose
Number of subjects: 10
Study 10677394 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of regular dose (50 mg/50 mg) of lactulose/rhamnose
Number of subjects: 10
Study 10677394 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of lactulose and rhamnose with accelerated small-bowel transit
Number of subjects: 10
Study 9313390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity weight‐bearing exercise program (thrice‐weekly for 12 weeks)
Number of subjects: 30
Study 9313390 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment (education program only)
Number of subjects: 30
Study 9313390 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity weight‐bearing exercise program
Number of subjects: 30
Study 8458054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil (30 mg/kg once daily for 10 days)
Number of subjects: 462
Study 8458054 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (30 mg/kg/day in two divided doses for 10 days)
Number of subjects: 462
Study 29443867 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV)
Number of subjects: 51
Study 29443867 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Exercise
Number of subjects: 51
Study 29443867 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study 29728298 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping using origin to insertion
Number of subjects: 42
Study 29728298 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping using insertion to origin
Number of subjects: 42
Study 29728298 — intervention group
Group type: COMPARATOR
Intervention: Control limb (non-dominant limb)
Number of subjects: 42
Study 27242317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1238 mg total cranberry (poly)phenols
Number of subjects: 10
Study 27242317 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study 24051077 — intervention group
Group type: EXPERIMENTAL
Intervention: tailored e‐SBI
Number of subjects: 143
Study 24051077 — intervention group
Group type: COMPARATOR
Intervention: time‐matched control condition
Number of subjects: 143
Study 22980168 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 2 sizes larger than FABF (Group A)
Number of subjects: 167
Study 22980168 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 3 sizes larger than FABF (Group B)
Number of subjects: 167
Study 22980168 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 4 sizes larger than FABF (Group C)
Number of subjects: 167
Study 22980168 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 5 sizes larger than FABF (Group D)
Number of subjects: 167
Study 22980168 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 6 sizes larger than FABF (Group E)
Number of subjects: 167